AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Biofidelity Raises $23M In Series A+ Financing Led By Octopus Ventures To Launch Aspyre Technology

Feb 01, 2022•over 3 years ago

Amount Raised

$23 Million

Round Type

series a

Cambridge

Description

Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company's first commercial diagnostic assay based on its breakthrough molecular technology.

Company Information

Company

Biofidelity

Location

Cambridge, Maryland, United States

About

Biofidelity is a pioneer in molecular diagnostics whose mission is to unlock the benefits of precision medicine for all patients by increasing access to early detection, precision diagnosis and routine monitoring with its revolutionary technologies. Founded in 2019 in Cambridge, UK, Biofidelity is a rapidly growing private company that recently expanded to include both a U.S. headquarters and state-of-the-art clinical cancer diagnostic laboratory located in Research Triangle Park, North Carolina. For more information, visit biofidelity.com or connect on LinkedIn.

Company News

(8 articles)

Thu, 09 Jan 2025 08:00:00 GMT

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials - PR Newswire

Thu, 20 Feb 2025 08:00:00 GMT

Biofidelity to launch Enspyre® technology at AGBT 2025 - PR Newswire

Tue, 24 Sep 2024 07:00:00 GMT

ASPYRE-Lung: validation of a simple, fast, robust and novel method for multi-variant genomic analysis of actionable NSCLC variants in FFPE tissue - Frontiers

Fri, 05 Apr 2024 07:00:00 GMT

Research Triangle-based Biofidelity raises $24 million - Business North Carolina

Tue, 02 Apr 2024 07:00:00 GMT

Biofidelity raises $24m to fast-track growth and expand pipeline - Business Weekly

Thu, 08 May 2025 07:00:00 GMT

SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER - PR Newswire

Wed, 26 Jun 2024 22:52:09 GMT

Evaluation and Validation of Thorax Model Responses: A Hierarchical Approach to Achieve High Biofidelity for Thoracic Musculoskeletal System - Frontiers

Thu, 17 Nov 2022 08:00:00 GMT

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director - PR Newswire

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech